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Abstract 
Physiological functions of the two extreme ends of the age spectrum, children (< 18 years old) and 
older adults (aged 65 years and over), differ from healthy young adults. This consequently affects the 
pharmacokinetic profiles of administered drugs, which, in turn, impacts upon clinical practice and drug 
therapy. The gastrointestinal milieu acts as a distinct and vital organ regulating the dissolution, 
absorption and metabolism of orally ingested drugs. Age-mediated alteration in the physiology and 
function of the gut can reshape the pharmacokinetics of certain drugs. However, our understanding 
on this topic is limited. This article references the gut physiology of healthy adults to capture the 
available evidence in the literature on the extent and nature of the changes in childhood and older 
age. The gut, as an organ, is examined with regards to the effect of age on luminal fluid, microbiota, 
transit and motility, and the intestinal mucosa. Whilst drastic developmental changes were observed 
in certain aspects of the gastrointestinal environment, the examination reveals significant gaps in our 
knowledge in the physiology and function of the developing or ageing gut.  The revelation of the 
unknown paves the way towards a better characterization of the human gastrointestinal tract for 
optimized drug therapy in children and older adults.  
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Figure 1. Postprandial time to return to pH 5, 4, 3 and 2 in elderly (65-83 years, n=79) and young (21-35 years, n=24) 
subjects. Figure plotted using data from (Russell et al., 1993). 
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Figure 2. Effect of age on the number of Peyer’s patches in human small intestine. B: before term (from 24 to 37 weeks 
gestation), A: after term (from birth to 95 years). Figure reproduced from (Cornes, 1965). 
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Figure 3. Effect of age on the number of Peyer’s patches in human small intestine in subjects up to 14 years of age. Figure 
plotted using data from (Cornes, 1965).  
y = 13.382x + 174.15
R² = 0.5408
0
100
200
300
400
500
-1 2 4 6 8 10 12 14
To
ta
l n
u
m
b
er
 o
f 
P
ey
er
's
 p
at
ch
es
 
in
 s
m
al
l i
n
te
st
in
e
Age (years)
[A]
y = -0.0014x + 0.4876
R² = 0.0042
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
-1 2 4 6 8 10 12 14
To
ta
l n
u
m
b
er
 o
f 
P
ey
er
's
 p
at
ch
es
 
p
er
 c
m
 s
m
al
l i
n
te
st
in
al
 le
n
gt
h
Age (years)
[B]
y = 37.236e-0.146x
R² = 0.6883
0
10
20
30
40
50
60
70
80
-1 2 4 6 8 10 12 14
To
ta
l n
u
m
b
er
 o
f 
P
ey
er
's
 p
at
ch
es
 
in
 s
m
al
l i
n
te
st
in
e 
 p
er
 K
g 
B
W
Age (years)
[C]
5 
 
 
Figure 4. Effect of age on the number of Peyer’s patches in human small intestine in subjects from 15 to 95 years of age. 
Figure plotted using data from (Cornes, 1965). 
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Figure 5. Effect of age on the number of lymphoid follicles per cm2 of human colon. Figure drawn using data from (Dukes 
and Bussey, 1926). 
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Figure 6. (a) Age related changes in the villi corrected expression of CYP3A4 in histologically normal duodenal sections. The 
numbers in each group are given in brackets and error bars are ± s.d. Statistical significance differences (P < 0.05) were 
achieved between foetus and all other groups and between neonate and children > 5 years. (b) Age related changes in 
villin corrected CYP3A4 activity measured by the rate of 6OHT formation in histologically normal duodenal sections. The 
numbers in each group are given in brackets and error bars are ± s.d. A statistically significant difference (P < 0.05) was 
observed only between neonates and children > 12 years. (Reproduced from (Johnson et al., 2001). 
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Figure 7. Effect of age on small intestinal transit time , figure adapted from [A] Madsen and Graff (2004) and [B] Fischer 
and Fadda (2016) 
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Table 1. Effects of ageing on the human gastrointestinal environment. 
GI characteristics Mean ± SD 
    Young Adult Elderly 
pH 8-14 y (n=12)[1] 18-65 y (n=39)[2]  65-83 y (n=79)[3] 
 Stomach 1.6 1.5 1.1-1.6 
 Small intestine (SI)    
 Duodenum 6.5 6.4 6.5 
 Jejunum 6.6 6.6  
 Mid SI 7.0 7.0  
 Distal SI 7.4 7.3  
 Caecum 5.9 5.7  
 Colon    
 Ascending 5.6 5.6  
 Transverse 5.5 5.7  
 Descending 6.0 6.6  
 Rectosigmoid  6.5 6.6  
 Faeces 6.4 6.5 6.57[4] 
Buffer Capacity (mmol/L/ΔpH)    
 Stomach  14 (20-32 y)[5]  
 Small intestine (SI)    
 Duodenum  18-30 (20-32 y)[5]  
 Jejunum  3.2 ± 1.3 [6]  
 Ileum  6.4 [6]  
 Caecum  -  
 Colon    
 Ascending  18.9 (20-30 y) [7]  
 Transverse    
 Descending    
 Rectosigmoid     
 Faeces    
Bile salts (mM), Duodemum    
 Fasted   1.6-5.9[10-16]  
 Fed 1.7 (under 2 days )[19] ~ 10[10-13, 17,18]  
 3.3 (2-7 days)[19]   
 8.5 (10 days to 7 mo)[19]   
Osmolality (mOsm.Kg-1)  226 ± 35 (18-25 y)ref 215 ± 37 (62-72 y)ref 
Gut associated lymphoid tissue (GALT)   
 SI (Peyer’s patches) [8] 222 ± 91 (0-14 y) 273 ± 67 (15-38 y) 181 ± 43 (41-95 y) 
 Colon (follicles/cm2) [9] 8.0 ± 2.3 (≤15 y) 4.0 ± 1.6 (16-40 y) 3.5 ± 1.6 (41-60 y) 
3.1 ± 1.6 (61-88 y) 
[1] Fallingborg et al 1990, [2] Fallingborg et al 1989, [3] Russell et al 1993, [4] Bouhnik et al 2007, [5] Kalantzi et al., 2006, [6] Fadda et al 
2010, [7] Diakidou et al., 2009, [8] Crones 1965ab, [9] Dukes and Bussey 1926, [10] (Armand et al., 1996), [11] (Clarysse et al., 2009), 
[12](Persson et al., 2005), [13] (Dressman et al., 1998), [14] (Lindahl et al., 1997), [15] (de la Cruz Moreno et al., 2006), [16] (Deferme et al., 
2003), [17] (Fausa, 1974), [18] (Kalantzi et al., 2006), [19] (Challacombe et al., 1975) 
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Table 2. Studies on the effect of aging on P-gp activity and expression in human. 
Parameter tested Cell type Effects of aging Reference 
P-gp activity B and T lymphocytes ↓ (Pilarski et al., 1995) 
P-gp expression T lymphocytes ↑ (Aggarwal et al., 1997) 
P-gp activiety ↑  
ABCB1 expression ↑  
P-gp expression Enterocytes → (Lown et al., 1997) 
P-gp activity B and T lymphocytes → or ↓ (Machado et al., 2003) 
P-gp activity Bone marrow stem cells → or ↑ (Calado et al., 2003) 
P-gp activity Natural killer cells → (Brenner and Klotz, 
2004) 
P-gp activity Blood-brain barrier ↓ (Toornvliet et al., 2006) 
ABCB1 expression Liver → (Prasad et al., 2014) 
P-gp activity Blood-brain barrier ↓ in male, → in female (van Assema et al., 
2012) 
P-gp activity  Intestine → (Larsen et al., 2007) 
P-gp expression Male lymphocytes ↑ (Vilas-Boas et al., 2011) 
P-gp activity →  
* Studies published prior to 2007 were adapted from (Mangoni, 2007). Increase (↑); decrease (↓); no change (→)
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Table 3. Selected studies on the composition of the faecal microbiota in children, adults and the elderly* 
Study 
population 
Age Total 
anaerobes 
Bacteroides Bifidobacterium Enterobactria Enterococci Clostridia Lactobacilli Reference 
Children 1 w  4.8 - 9.3 6.2 - 10.2 6.2 - 9.4 5.7 - 9.0 3.1 - 7.2 4.4 - 7.0 (Adlerberth and Wold, 2009)† 
5 w  6.0 - 10.1 4.3 - 11.3 6.1 - 9.6 4.5 - 9.6 3.0 - 8.1 5.0 - 9.1 (Adlerberth and Wold, 2009)† 
1 m  9.40 (5.74-
10.36) 
10.71 (6.84-11.56)   5.24 (2.70-
9.57) 
8.70 (7.92-
10.73) 
(Scheepers et al., 2015) 
16 m - 7 y 10.4 ± 0.2 9.9 ± 0.4 9.8 ± 0.3 8.0 ± 0.4 5.5 ± 0.5 7.2 ±0.8 6.6 ± 0.7 (Hopkins et al., 2002) 
Adults 21 - 34 y 10.5 ± 0.1 10.0 ± 0.1 9.1 ± 0.2 5.9 ± 0.5 6.1 ± 0.7 6.6 ± 0.4 6.7 ± 0.6 (Hopkins et al., 2002) 
19 - 35 y  9.9 ±  0.1  9.5 ±  0.2 5.8 ±  0.6 6.5 ±  0.9 5.6 ±  1.0 6.3 ±  1.0 (Woodmansey et al., 2004) 
21 - 39 y 9.11 9.42 9.54     (Tiihonen et al., 2008) 
Elderly 67 - 88 y 10.1 ± 0.2 9.6 ± 0.2 7.3 ± 1.0 6.7 ± 0.8 6.0 ± 0.8 6.9 ± 0.6 5.4 ± 1.0 (Hopkins et al., 2002) 
67 - 75 y  6.5 ± 2.1 8.1 ± 1.6 7.3 ± 0.4  5.3 ± 1,7 4.1 ± 1.8 (Woodmansey et al., 2004) 
> 62 y 10.3 ± 0.5  8.6 ± 1.0    6.0 ± 1.4 (Bartosch et al., 2005) 
69 ± 2 y 10.09 ± 0.07  8.5 ± 0.26 7.69 ± 0.21  3.25 ± 0.25  (Bouhnik et al., 2007) 
77 - 97 y   8.8 6.0 7.7 6.1 3.5 5.1 (Guigoz et al., 2002) 
68 - 84 y 9.29 9.59 9.59         (Tiihonen et al., 2008) 
*Amounts are given as log10 number of bacteria/g fresh faecal weight, †Adapted from reference (Adlerberth and Wold, 2009), summarising studies on intestinal microbiota in children performed 
until 1990.  
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Conclusion and future perspectives 
Age is an important determinant that impacts on the absorption and metabolism of drugs. It is 
apparent from this paper that many physiological and functional aspects of the human gut differ in 
children and older individuals from young adults. However, there are many knowledge gaps on age-
related changes in the gut. The heterogeneity of both age groups further complicates the situation, as 
children do not develop at the same rate nor do the elderly age uniformly. Considering the rareness 
of healthy older patients, individual studies should be conducted on the geriatric population with co-
morbidities and multiple medications, to consider the potential influence of concomitant diseases on 
the in-vivo fate of the drug in the gastrointestinal tract. Equally, further understanding on the 
chronological age-related changes (only healthy young and healthy older age-related) in the gut is 
important. In the case of the elderly, frailty should be a better indicator for the aged-gut compared to 
chronological age as the ageing status should be ideally defined by connecting the decline in 
physiological capacity and increased risk of vulnerability to disease. 
Children and older patients are often underrepresented in clinical trials resulting in a lack of evidence 
based information on the effect of ageing on oral drug bioavailability. Although it is known that the 
function of GI tract is altered during developmental stages or with advanced age, the effects on 
pharmacokinetics and/or pharmacodynamics of the orally administered drug are often unclear. This 
data obtained from children and older subjects is essential as the prediction of clinical outcomes based 
on the gut physiological changes and/or extrapolation from healthy young adults may not be 
appropriate. The impact of prediction tools (e.g. physiologically-based pharmacokinetic 
/pharmacodynamics modelling and simulation) should be further explored to inform clinical trials in 
younger and older populations. Age related changes in barriers to drug delivery should be available to 
formulation scientists and adequately reflected in the design of personalized formulations to ensure 
the development of high quality, safe and effective drug therapies for use in young and older patients. 
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